Novoprotein(SH:688137)2022-10-27 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥46,292,353.53, a decrease of 68.40% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥18,802,760.66, down 74.78% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,438,667.48, a decline of 76.61% compared to the previous year[5] - Basic earnings per share for Q3 2022 were ¥0.3573, down 77.20% from the same period last year[6] - Total operating revenue for the first three quarters of 2022 was CNY 212,629,893.17, a decrease of 23.4% compared to CNY 277,583,731.81 in the same period of 2021[23] - Net profit for the first three quarters of 2022 was CNY 90,105,051.52, a decline of 29.5% from CNY 127,816,354.33 in the same period of 2021[24] - Basic and diluted earnings per share for the first three quarters of 2022 were CNY 1.71, compared to CNY 3.52 in the same period of 2021[25] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥9,898,324.44, reflecting a decrease of 79.42%[6] - The company experienced a net cash outflow from operating activities, indicating potential liquidity challenges moving forward[27] - Net cash flow from operating activities was $9,898,324.44, a decrease of 79.5% compared to $48,091,554.69 in the previous year[28] - Total cash inflow from financing activities reached $1,764,560,776.77, significantly up from $117,670,174.00 in the same quarter last year[29] - Cash and cash equivalents at the end of the period totaled $1,698,855,837.31, compared to $188,009,100.59 at the end of the previous year[29] - The net increase in cash and cash equivalents for the quarter was $1,509,464,027.27, compared to $119,369,848.87 in the same quarter last year[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,363,348,720.91, an increase of 360.60% compared to the end of the previous year[6] - Total liabilities as of the end of Q3 2022 were CNY 166,373,101.81, an increase from CNY 153,330,102.24 at the end of Q3 2021[20] - The company reported a decrease in accounts payable from ¥44,023,181.57 to ¥23,638,448.18, a reduction of approximately 46.3%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,882[14] - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 30,355,000 shares, accounting for 43.26% of total shares[14] - Total equity attributable to shareholders of the parent company was CNY 2,196,975,619.10, significantly up from CNY 359,772,635.07 in the previous year[20] Research and Development - Research and development expenses totaled ¥10,474,557.34, representing 22.63% of operating revenue, an increase from 14.23% in the previous year[6] - The company reported a decrease in research and development expenses to CNY 28,484,447.30 from CNY 24,221,352.19 year-over-year[23] - The company has no new product or technology developments mentioned in the report[16] Market and Sales - The company experienced a significant decline in sales to Watson Bio, which impacted overall revenue and profit margins[11] - Cash received from sales of goods and services in the first three quarters of 2022 was CNY 197,109,482.47, a decrease from CNY 212,553,150.08 in the same period of 2021[27] Investment Activities - Cash outflow from investment activities was $262,449,345.66, compared to $202,609,530.23 in the previous year, indicating an increase of 29.5%[28] - The company did not recover any cash from investments during the quarter, compared to $177,000,000.00 in the same quarter last year[28] - The company reported cash inflow from investment activities of $9,900.00, a significant decrease from $177,995,853.12 in the previous year[28] Other Financial Metrics - The weighted average return on net assets decreased by 35.40 percentage points to 4.23%[6] - Accounts receivable increased to ¥118,583,615.61 from ¥96,578,245.44 year-over-year, reflecting a growth of approximately 22.8%[18] - Inventory levels rose to ¥77,286,267.89, compared to ¥37,190,793.04 in the previous year, indicating a growth of about 107.5%[18] - Non-current assets total ¥199,434,079.17, an increase from ¥180,879,944.65 year-over-year[19] - Deferred income tax liabilities decreased to CNY 2,754,053.35 from CNY 3,207,786.27 year-over-year[20] - The company paid $82,686,173.84 in employee compensation, an increase from $49,905,981.37 in the previous year[28] - Total cash outflow from financing activities was $5,198,826.28, down from $21,525,576.81 in the previous year, reflecting a decrease of 75.8%[29]